You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Seattle, Washington 98109

  • Anemia, Aplastic


A single arm dose optimization study in which all patients are given a fixed dose of Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy is escalated or de-escalated dependent upon engraftment and toxicity.


Inclusion Criteria: - Life-threatening marrow failure of nonmalignant etiology; - failure to respond to the best available immunosuppressive treatment; - lack of a HLA-identical family member Exclusion Criteria: - Severe disease other than aplastic anemia that would severly limit the probability of survival during the graft procedure; - HIV seropositive patients; - clonal abnormalities or myelodysplastic syndrome;



Primary Contact:

Principal Investigator
Joachim Deeg, M.D.
Fred Hutchinson Cancer Research Center

Backup Contact:


Location Contact:

Seattle, Washington 98109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.